Paper27522158
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.
Povsic TJ and 15 others. J Allergy Clin Immunol, 2016. Cited by 160 papers, by iCite.
Cite this record
ConductScience Library. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. Papers, record 27522158. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27522158
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies | Major topic |
| Aptamers, Nucleotide | Major topic |
| Hypersensitivity, Immediate | Major topic |
| Polyethylene Glycols | Major topic |
| Clinical Trials, Phase III as Topic | |
| Humans | |
| Multicenter Studies as Topic | |
| Randomized Controlled Trials as Topic |
Source PubMed
Cited by96
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 160 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42963446 | Complement Activation-Related Pseudoallergy (CARPA): An Underrecognized Risk of Drugs, Drug Carriers, and Formulation Vehicles. | Clin Rev Allergy Immunol | 2026 | https://conductscience.org/library/papers/42963446 | PubMed |
| 42514893 | Anti-PEG Immunogenicity of mRNA-LNP Vaccines in Humans: Evidence for Population-Level Changes in the Anti-PEG Antibody Repertoire. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42514893 | PubMed |
| 42149311 | Protein-protein interaction disruption as a next-generation antithrombotic strategy. | J Thromb Thrombolysis | 2026 | https://conductscience.org/library/papers/42149311 | PubMed |
| 42098447 | Recent advances in the regulation of CD47 by non-coding RNAs and its therapeutic potential in cancer. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42098447 | PubMed |
| 41898181 | From Selection to Use: Aptamers as Targeting Reagents in Hematology. | Biomedicines | 2026 | https://conductscience.org/library/papers/41898181 | PubMed |
| 41141388 | In vivo gene therapy: A strategy for mutations, degenerations, and tumors. | Genes Dis | 2026 | https://conductscience.org/library/papers/41141388 | PubMed |
| 41065938 | Critical appraisal of "Precision nanotherapeutics for kidney disease: targeting inflammation and maladaptive repair". | Int Urol Nephrol | 2026 | https://conductscience.org/library/papers/41065938 | PubMed |
| 40871093 | Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40871093 | PubMed |
| 40682687 | Advancements in hydroxypropyl methylcellulose-polyethylene glycol hybrid excipients and their nanoformulations for controlled and ligand-directed biologic delivery. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40682687 | PubMed |
| 40599554 | Rats subject to extracorporeal membrane oxygenation have improved cardiac function following anticoagulation and reversal with factor IXa aptamer-antidote oligonucleotide pair. | Cardiol Plus | 2025 | https://conductscience.org/library/papers/40599554 | PubMed |
| 40574110 | Implications of Anaphylaxis Following mRNA-LNP Vaccines: It Is Urgent to Eliminate PEG and Find Alternatives. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40574110 | PubMed |
| 39978660 | RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases. | Pharmacol Res | 2025 | https://conductscience.org/library/papers/39978660 | PubMed |
| 39157078 | Impact of the Hydrophilicity of Poly(sarcosine) on Poly(ethylene glycol) (PEG) for the Suppression of Anti-PEG Antibody Binding. | ACS Omega | 2024 | https://conductscience.org/library/papers/39157078 | PubMed |
| 39119697 | Liposomes with Low Levels of Grafted Poly(ethylene glycol) Remain Susceptible to Destabilization by Anti-Poly(ethylene glycol) Antibodies. | ACS Nano | 2024 | https://conductscience.org/library/papers/39119697 | PubMed |
| 38612441 | Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38612441 | PubMed |
| 38469811 | Free PEG Suppresses Anaphylaxis to PEGylated Nanomedicine in Swine. | ACS Nano | 2024 | https://conductscience.org/library/papers/38469811 | PubMed |
| 38400143 | Right Biceps Pseudo-Tumor from COVID-19 Vaccination. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/38400143 | PubMed |
| 38394369 | Antiviral Protein-Protein Interaction Inhibitors. | J Med Chem | 2024 | https://conductscience.org/library/papers/38394369 | PubMed |
| 38182056 | Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy. | J Control Release | 2024 | https://conductscience.org/library/papers/38182056 | PubMed |
| 38162136 | Bivalirudin-hydrogel coatings of polyvinyl chloride on extracorporeal membrane oxygenation for anticoagulation. | Front Cardiovasc Med | 2023 | https://conductscience.org/library/papers/38162136 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27522158
GET https://conductscience.org/api/papers/v1/27522158/cited_by?page=2